OKYO Pharma Ltd (NASDAQ:OKYO) announced that its chief medical officer Flavio Mantelli purchased 20,000 ordinary shares of the clinical-stage biopharmaceutical company on the Nasdaq at $1.40 per share.
The company is developing treatments for neuropathic corneal pain and anterior segment eye diseases.
OKYO said it plans to begin a global Phase 3 pivotal trial in the second half of 2026 to evaluate a single-dose regimen of urcosimod for neuropathic corneal pain.